Search results
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
FOX 59 Indianapolis· 11 hours agoFood and Drug Administration ("FDA") has now determined that its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome is entitled to a Priority ...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 1 day ago(NASDAQ:OCUL) (“Ocular”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet ...
Vision-Language Models for Feature Detection of Macular Diseases on Optical Coherence Tomography
Journal of the American Medical Association· 6 days agoThis cross-sectional study evaluates the performance of a vision-language model in performing ophthalmologic tasks related to interpretation of optical coherence tomography scans.
EyePoint tumbles 30% premarket on failed Phase 2 study (NASDAQ:EYPT)
Seeking Alpha· 2 days agoEyePoint (EYPT) stock tumbled nearly 30% in premarket trading Monday after the company said a Phase...
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Benzinga via Yahoo Finance· 1 day agoOn Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2...
Research to Prevent Blindness Opens Applications for Vision Research Grants
Newswise· 3 days ago(RPB) is pleased to announce that it has opened a new round of grant funding for high-impact vision research. With a focus on scientific excellence, RPB funds research across all sight-threatening ...
EyePoint reports mixed results in diabetic retinopathy trial By Investing.com
Investing.com· 1 day agoEyePoint Pharmaceuticals, Inc. (NASDAQ: NASDAQ:EYPT) announced interim results from its Phase 2...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 6 days agoWhile development potential and interest for this novel treatment approach is high for more rare inherited conditions such as retinitis pigmentosa and Stargardt's, Spherix's ...
EyePoint Pharmaceuticals stock target cut, retains Buy rating By Investing.com
Investing.com· 14 hours agoThe reduction follows a significant 43% drop in EyePoint's share value on Monday, which contrasted...
Seven Things Everyone Should Know About Retina Specialists
Newswise· 7 days agoMillions of Americans have retina specialists to thank for saving their vision from conditions such as age-related macular degeneration (AMD) and diabetic ...